CpG DNA and LPS induce distinct patterns of activation in human monocytes

Gene Therapy

Volumn 6, Issue 5, 1999, Pages 893-903

  Hartmann, G ^a   Krieg, A M ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CpG; DNA vaccination; Endotoxin; Gene therapy; Oligodeoxynucleotide; Therapeutic DNA

Indexed keywords

BACTERIAL DNA; CYTOKINE; DNA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; OLIGODEOXYNUCLEOTIDE; TUMOR NECROSIS FACTOR;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; LEUKOCYTE ACTIVATION; MONOCYTE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL;

CELLS, CULTURED; CPG ISLANDS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE THERAPY; HUMANS; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MURINAE;

EID: 0033027749     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300880     Document Type: Article

References (54)

1. Davis HL. Plasmid DNA expression systems for the purpose of immunization. Curr Opin Biotechnol 1997; 8: 635-646.
2. Hartmann G et al. Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 1996; 6: 291-299.
3. Branch AD. A good antisense molecule is hard to find. Trends Biochem Sci 1998; 23: 45-50.
4. Agrawal S, Iyer RP. Perspectives in antisense therapeutics. Pharmacol Ther 1997; 76: 151-160.
5. Krieg AM et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.
6. Krieg AM, Yi AK, Schorr J, Davis HL. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 1998; 6: 23-27.
7. Krieg AM. An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med 1996; 128: 128-133.
8. Krieg AM. Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol 1996; 4: 73-76.
9. Sato Y et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352-354.
10. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997; 158: 3635-3639.
11. Hartmann G et al. Cytokines and therapeutic oligonucleotides. Cytok Cell Molec Ther 1997; 3: 247-256.
12. Krieg A. How to exclude immunostimulatory effects of antisense oligonucleotides. In: Hartmann G, Endres S (eds). Manual of Antisense Methodology. Kluwer Academic: Boston, 1999 (in press).
13. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998; 16: 1216-1224.
14. Davis HL et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998; 160: 870-876.
15. Weiner GJ et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997; 94: 10833-10837.
16. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997; 89: 2994-2998.
17. Roman M et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nature Med 1997; 3: 849-854.
18. Chu RS et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186: 1623-1631.
19. Kline JN et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160: 2555-2559.
20. Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 1998; 161: 2428-2434.
21. Zimmermann S et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 1998; 160: 3627-3630.
22. Freund J, Casals J, Hosmer EP. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc Soc Exp Biol Med 1937; 37: 509-513.
23. Freund J, McDermot K. Sensitization to horse serum by means of adjuvants. Proc Soc Exp Bio NY 1942; 49: 548-553.
24. Herbert WJ. Mineral-oil adjuvants and the immunization of laboratory animals. In: Weir DM (ed). Handbook of Experimental Immunology. Blackwell Scientific: Oxford, 1978, pp 179-193.
25. Yamamoto S et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 1992; 36: 983-997.
26. Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 1991; 147: 1759-1764.
27. Munoz J. Effect of bacteria and bacterial products on antibody response. Adv Immunol 1964; 4: 397-440.
28. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996; 157: 2116-2122.
29. Sweet MJ et al. IFN-gamma primes macrophage responses to bacterial DNA. J Interferon Cytok Res 1998; 18: 263-271.
30. Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today 1996; 17: 214-217.
31. Eigler A, Sinha B, Hartmann G, Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997; 18: 487-492.
32. Chace JH et al. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol 1997; 84: 185-193.
33. Cowdery JS, Chace JH, Yi AK, Krieg AM. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996; 156: 4570-4575.
34. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 1840-1845.
35. Yi AK, Chace JH, Cowdery JS, Krieg AM. IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol 1996; 156: 558-564.
36. Yi AK et al. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol 1996; 157: 5394-5402.
37. Klinman DM et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996; 93: 2879-2883.
38. Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol 1998; 160: 1122-1131.
39. Yamamoto T et al. Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn J Cancer Res 1994; 85: 775-779.
40. Liang H et al. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest 1996; 98: 1119-1129.
41. Branda RF et al. B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin Immunol Immunopathol 1996; 79: 115-121.
42. Branda RF et al. Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J Lab Clin Med 1996; 128: 329-338.
43. Yi AK et al. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 1998; 160: 4755-4761.
44. Gao JX et al. Generation of dendritic cell-like antigen-presenting cells in long-term mixed leucocyte culture: phenotypic and functional studies. Immunology 1997; 91: 135-144.
45. Yacyshyn BR et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114: 1133-1142.
46. Ohta Y et al. Direct antigen presentation through binding of donor intercellular adhesion molecule-1 to recipient lymphocyte function-associated antigen-1 molecules in xenograft rejection. Transplantation 1998; 65: 1094-1100.
47. Taguchi M et al. Patterns for RANTES secretion and intercellular adhesion molecule 1 expression mediate transepithelial T cell traffic based on analyses in vitro and in vivo. J Exp Med 1998; 187: 1927-1940.
48. Sparwasser T et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol 1997; 27: 1671-1679.
49. Schwartz DA et al. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J Clin Invest 1997; 100: 68-73.
50. Sartor RB. Review article: how relevant to human inflammatory bowel disease are current animal models of intestinal inflammation? Aliment Pharmacol Ther 1997; 3: 89-96.
51. Elson CO, Sartor RB, Tennyson GS, Riddel RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109: 1344-1367.
52. Sun S, Kishimoto H, Sprent J. DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J Exp Med 1998; 187: 1145-1150.
53. Hartmann G, Krug A, Waller-Fontaine K, Endres S. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin. Mol Med 1996; 2: 429-438.
54. Hartmann G et al. Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J Pharmacol Exp Ther 1998; 285: 920-928.